Response Biomedical Corporation Announces Appointment of Jeffrey L. Purvin as Director & CEO and Resignation of Peter Thompson as Interim CEO

VANCOUVER, BRITISH COLUMBIA--(Marketwire - July 25, 2012) - Response Biomedical Corporation (TSX:RBM)(OTCBB:RPBIF) today reported that effective July 25, 2012, the Board of Directors of the Company have appointed Mr. Jeffrey L. Purvin as a Director and Chief Executive Officer.

Mr. Purvin has over 30 years of experience marketing both consumer and medical products and is a member of the Board of Directors at Cardica, Inc. He is Chair of Cardica's Compensation Committee and is a member of its Audit and Finance Committees. Mr. Purvin earned a B.A. from Brown University and an M.B.A from The Wharton School, University of Pennsylvania.

The Company also wishes to announce the resignation of Dr. Peter A. Thompson as Interim Chief Executive Officer effective July 25, 2012. The Company thanks Dr. Thompson for his leadership and contributions as Interim Chief Executive Officer over the last eleven months and is pleased to note that Dr. Thompson will remain as Executive Chairman of the Company's Board of Directors.

Further information on the Company can be found at www.responsebio.com, SEDAR (Canada) www.sedar.com or EDGAR (U.S.) www.sec.gov/edgar/searchedgar/webusers.htm. Information at these sites is typically available within 24 hours of the distribution of the news release.

About Response Biomedical

Response Biomedical develops, manufactures and markets rapid on-site diagnostic tests for use with its RAMP^® platform for clinical and environmental applications. RAMP^® represents a new paradigm in diagnostics that provides high sensitivity and reliable information in minutes. It is ideally suited to both point of care testing and laboratory use.

The RAMP^® system consists of a reader and single-use disposable test cartridges, and has the potential to be adapted to more than 250 medical and non-medical tests currently performed in laboratories. RAMP^® clinical tests are commercially available for the early detection of heart attack and congestive heart failure through our commercial partners and distributors.

In the non-clinical market, RAMP^® Tests are currently provided for the environmental detection of West Nile Virus, and Biodefense applications including the rapid on-site detection of anthrax, smallpox, ricin and botulinum toxin.

Response has achieved CE Marking for its readers and clinical tests and its Quality Management System is registered to ISO 13485: 2003 and ISO 9001: 2008.

Response Biomedical is a publicly traded company listed on the TSX under the trading symbol "RBM" and quoted on the OTC Bulletin Board under the symbol "RPBIF". For further information, please visit the Company's website at www.responsebio.com.

About the RAMP^® Reader and RAMP^® 200 reader

The RAMP^® enabling platform is a portable scanning fluorescence quantitative analysis platform for near patient testing that enables rapid and robust quantitative results. The platform includes easy software upgrades, data management capabilities and unique interface options. The RAMP^® Reader features a small footprint and attractive ease of use for moderate throughput settings. The RAMP^® 200 reader has innovative design features, including the multi-port capability to run 18 tests per hour on one module and up to 36 tests per hour, using three modules. This allows tests to be run on multiple patients simultaneously or multiple assays to be run for one patient. More information on our proprietary RAMP^® technology can be found at www.responsebio.com.

Forward-Looking Statements

This press release may contain forward-looking statements. These statements relate to future events and are subject to risks, uncertainties and assumptions about Response Biomedical Corporation. Examples of forward-looking statements in this press release include statements regarding our expectations for the appointment of a new CEO and the expected start date of that individual.

These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. Many factors may cause our actual results to differ materially from any forward-looking statement, including the factors detailed in our filings with the Securities and Exchange Commission and Canadian securities regulatory authorities, including but not limited to our annual report on Form 10-K, our Annual Information Form and other filings with the Securities and Exchange Commission and Canadian securities regulatory authorities. We do not undertake to update any forward-looking statements.